NONOF
Novo Nordisk A/S OTC$44.70
Mkt Cap $198.6B
52w Low $34.00
22.1% of range
52w High $82.50
50d MA $38.21
200d MA $49.86
P/E (TTM)
1.8x
EV/EBITDA
10.4x
P/B
1.0x
Debt/Equity
0.7x
ROE
61.1%
P/FCF
24.5x
RSI (14)
—
ATR (14)
—
Beta
0.27
50d MA
$38.21
200d MA
$49.86
Avg Volume
286.7K
About
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | TNS | 0.92 | 0.95 | +2.8% | 50.00 | -5.0% | -5.6% | -10.7% | -3.8% | +1.5% | -1.0% | — |
| Nov 5, 2025 | TNS | 0.77 | 0.71 | -7.9% | 49.25 | -0.5% | -4.0% | -8.0% | -5.1% | -1.4% | +0.5% | — |
| Aug 6, 2025 | TNS | 0.94 | 0.94 | +0.5% | 45.50 | +3.3% | +5.8% | +10.9% | +9.0% | +9.0% | +10.0% | — |
| May 7, 2025 | TNS | 0.89 | 0.96 | +8.6% | 66.00 | +0.7% | -3.0% | -1.3% | +1.4% | -2.3% | -3.0% | — |
| Feb 5, 2025 | TNS | 0.83 | 0.88 | +5.9% | 85.45 | +1.4% | +1.8% | +0.1% | +0.4% | -1.8% | -4.5% | — |
| Nov 6, 2024 | TNS | 0.90 | 0.92 | +2.5% | 110.60 | -0.5% | -4.2% | +0.1% | -2.5% | -4.7% | -5.2% | — |
| Aug 7, 2024 | TNS | 0.70 | 0.65 | -7.0% | 119.50 | +2.5% | +5.4% | +11.6% | +7.0% | +12.0% | +11.9% | — |
| May 2, 2024 | TNS | 0.75 | 0.82 | +8.2% | 124.22 | -1.0% | -2.2% | -0.4% | +0.0% | +2.2% | +2.8% | — |
| Mar 7, 2024 | TNS | 0.68 | 0.72 | +6.8% | 135.95 | +1.3% | -3.2% | -3.8% | -1.3% | -2.4% | -0.9% | — |
| Sep 30, 2023 | TNS | 0.68 | 0.71 | +4.0% | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | BTIG | Maintains | Buy → Buy | — | $76.03 | $78.38 | +3.1% | +1.6% | +1.7% | +2.2% | +2.7% | +3.5% |
| Dec 11 | TD Cowen | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Jun 27 | UBS | Downgrade | Neutral → Sell | — | $54.75 | $55.00 | +0.5% | +0.8% | +1.7% | -0.1% | +1.8% | +3.1% |
| Jun 6 | JP Morgan | Upgrade | Neutral → Overweight | — | $55.73 | $58.00 | +4.1% | -0.1% | +2.5% | +3.7% | +0.8% | -3.1% |
| May 30 | Guggenheim | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Mar 15 | Deutsche Bank | Upgrade | Hold → Buy | — | $52.13 | $53.12 | +1.9% | -1.4% | -1.1% | +2.1% | +7.5% | +5.4% |
| Jan 24 | Liberum | Downgrade | Hold → Sell | — | $47.55 | $45.86 | -3.6% | +0.6% | -0.6% | +0.4% | +3.0% | +2.1% |
| Dec 19 | JP Morgan | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Jan 2 | Guggenheim | Downgrade | Buy → Neutral | — | $28.93 | $28.84 | -0.3% | -0.3% | -1.1% | -2.1% | -2.2% | -2.8% |
| Nov 17 | UBS | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
Data updated apr 27, 2026 7:41pm
· Source: massive.com